Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 30, 2024

BUY
$14.19 - $42.33 $95,456 - $284,753
6,727 New
6,727 $276,000
Q3 2022

Nov 14, 2022

BUY
$41.87 - $57.99 $220,236 - $305,027
5,260 New
5,260 $234,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.02B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Cornercap Investment Counsel Inc Portfolio

Follow Cornercap Investment Counsel Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cornercap Investment Counsel Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cornercap Investment Counsel Inc with notifications on news.